Study of NKX019 for immune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of these conditions: scleroderma, myositis, vasculitis, or rheumatoid arthritis, and it is active despite prior treatments.
- Your kidney function is at least moderately good (eGFR 45 or higher).
- You have not had a prior organ or stem cell transplant.
- You do not have active serious infections, recent major heart problems, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.